To evaluate the role of caveolin-1 (Cav-1) as a predictor of disease reclassification (DR) in men with early prostate cancer undergoing active surveillance (AS).
Introduction
The last decade witnessed a paradigm shift to managing lowrisk prostate cancer with active surveillance (AS), not only in academic centres but also in community-based practices [1] . In part because prostate cancer's biological behaviour varies widely and early disease progression is not clearly defined, there is no consensus about surveillance for early prostate cancer, including selection criteria for eligibility or clinicopathological changes constituting disease progression [2] .
The AS management option is based on the tenet that the natural history of prostate cancer is predictable. Although the molecular basis of disease progression in early prostate cancer is not well delineated, we know from next-generation sequencing studies in advanced prostate cancer that molecular changes accompanying histological changes in early prostate cancer progression may not be linear, suggesting tumour heterogeneity [3] . Additionally, prostate biopsy, the primary method of characterizing disease, is vulnerable to inherent sampling bias (undersampling), which threatens identification of true disease progression. In radical prostatectomy series of patients considered eligible for AS,~30% are found to have upstaging and upgrading at prostatectomy [4] . Based on the results of AS cohorts with at least 5 years of follow-up, 24-40% of patients on AS will pursue active treatment and 0.1-2.8% will develop metastatic disease [5] .
To improve risk stratification, individualize monitoring strategy, and reduce active treatment during AS, we need to refine patient selection at diagnosis with biomarkers. Given the morbidities [6] of and limited tumour tissue from prostate biopsies, identifying circulating biomarkers able to distinguish indolent from aggressive disease and able to predict early disease progression could transform management.
Caveolin-1 (Cav-1), a major structural component of caveolae, is secreted by prostate cancer cells and associated with malignant progression through multiple mechanisms and signalling pathways [7] . We have shown that Cav-1 is implicated in the transition from high-grade prostatic epithelial neoplasia to prostate cancer through c-Myc regulation and Akt signalling induction [8] . Other studies show that Cav-1 levels rise during prostate cancer progression and mediate resistance to hormone therapy [9, 10] by inducing glycolytic activities in prostate cancer cells and promoting hormone resistance under androgen deprivation through upregulation of acetyl-CoA carboxylase 1 and fatty acid synthase [10, 11] . Finally, investigations show serum Cav-1 levels are associated with high-risk prostate cancer [12] , with biochemical recurrence after prostatectomy [13] , and, when levels are high, with castration-resistant prostate cancer rather than with hormonenaive disease when levels are high [14] .
Hypothesizing that Cav-1 participates in disease progression in early prostate cancer, we evaluated Cav-1 as a biomarker for upgrading and disease reclassification (DR). We used archived plasma samples from men undergoing AS, which we also used to assess longitudinal measurements of Cav-1 in early disease progression.
Materials and Methods
We used archived plasma samples prospectively collected from patients with early prostate cancer who participated in a single-institution cohort study of AS at The University of Texas MD Anderson Cancer Center, as reported previously [15] . The study (clinicaltrials.gov NCT00490763) was initiated in February 2006, and 825 patients had enrolled by February 2014. The institutional review board approved the protocol, and all enrollees provided signed informed consent. Patients with clinically organ-confined prostate cancer diagnosed within 6 months of study enrolment were stratified to one of three groups. Enrolment in group I included those with favourable risk and required no more than one core of 3+3 Gleason score (GS; tumour focus <3.0 mm) or 3+4 GS (tumour focus <2.0 mm). The study-entry PSA level was <4 ng/mL, or was adjusted for prostate volume [16] . Group II included patients with a 3+3 GS or 3+4/4+3 GS who did not meet group I criteria and chose AS. Group III included patients with comorbidities that precluded local therapy, as determined by the physician treating the patient. Twice-yearly clinical examination, laboratory study and biopsy protocols along with protocol amendments are reported elsewhere [15] .
At twice-yearly clinical examinations, a DRE and laboratory studies (levels of testosterone and serum PSA level), recording of concomitant medications, including 5a-reductase inhibitors and statins, and body mass index were carried out. In 2014, scheduling of post-baseline measures of testosterone was amended to an annual schedule. Biopsy of the prostate was performed every 1-2 years; the following year's biopsy was omitted if the biopsy was negative, unless requested by the patient. Biopsies were performed via a standard approach using TRUS, and samples were taken according to the 11-core multisite-directed scheme that included sextant locations, one posterior midline, and left and right anterior horns [17] .
At repeat biopsy, having an increase in tumour volume (increase in the number of positive cores and/or total tumour length) or any Gleason grade 4 or 5 component led to DR. For three patients in group II who had a primary Gleason grade 4 component in Gleason score 7 tumours, any primary Gleason grade 5 led to DR. Investigators did not reclassify disease based on the location of disease, including when it was found in the contralateral lobe, if the repeat biopsy otherwise met criteria for stable disease. A PSA change of a >30% increase from baseline was considered clinically significant, and the level was retested 1 month later or 3 months after biopsy. Given that an elevated PSA level triggers additional tests, no patient came off study solely based on the elevated PSA level. No multiparametric endorectal MRI was required at baseline, and during surveillance it was left to the managing physician as to whether MRI was indicated for cause (e.g. mismatching PSA level and pathological findings on biopsy). Patients remained on protocol until they requested withdrawal, chose active treatment after DR, or were diagnosed with a second malignancy. With the managing physician's agreement, patients who declined repeat biopsy could stay on protocol.
Additionally, we calculated for each case the University of California, San Francisco, Cancer of the Prostate Risk Assessment (CAPRA) score [18, 19] . To calculate PSA velocity, we fit a linear regression model on In(PSA) values over time. A reliable measure of PSA velocity requires, according to the AUA, at least three measures of PSA after diagnosis over 18 months [20] . To calculate PSA doubling time, we regressed In(PSA) over time, obtaining the slope m and defining it as In (2) Venous blood was collected into one 10-mL EDTA-coated tube (Becton Dickinson, Franklin Lakes, NJ, USA) at baseline and every 6 months during surveillance as an optional procedure. The Vacutainer was inverted gently to allow proper additive mixture. Samples were centrifuged at 4°C for 20 min at 1000-1200g. The supernatant was removed, and vial contents were aliquoted into multiple cryovials (minimum of three). Blood samples were processed and frozen within 2 hr of collection. Cav-1 was measured using a direct sandwich ELISA, as previously described [13, 21] . To the best of our knowledge there is no available commercial assay to measure Cav-1 levels. We have described characterization of the ELISA parameters, including the interassay and intra-assay coefficient of variability in our previous publication [21] .
Patient characteristics were summarized using median and range for continuous variables and frequency with percentage for categorical variables. The skewed distribution prompted application of logarithmic transformation after shifting Cav-1 values by 1. The log-transformed Cav-1 at each time point was summarized using descriptive statistics. A BLiP plot was used to show the distribution of log-transformed Cav-1 over time. Patient characteristics of those with and without DR were compared using the Wilcoxon rank sum test for continuous variables and the chi-squared test or Fisher's exact test for categorical variables.
Univariate logistic regression analyses were performed to assess the association between each patient characteristic and risk of DR. The optimum threshold for Cav-1 was selected based on the Youden index [22] . A multiple logistic regression model was fit by including all covariates that were statistically significant in the univariate analysis, and a scoring system was developed based on the multivariate logistic regression model for predicting risk of DR. The assigned score for each covariate was determined based on the estimated odds ratio (OR) obtained from the regression model. A bootstrapping method was used to validate the scoring system. Statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA) and R (R Foundation for Statistical Computing, Vienna, Austria).
Results

Study Cohort
Of 825 patients enrolled between February 2006 and February 2014, 616 had at least 1 year of follow-up. Of these, 542 patients in groups I and II had baseline blood specimens. Two patients with GS5 tumours in groups I and II, and 14 patients in group III were excluded. Baseline patient characteristics by DR status show that 163 patients (30.1%) were reclassified, and of these, 86 reached the DR threshold because of tumour upgrading (Table 1) . These patients were more likely to be older (P = 0.04) and have longer total tumour length at baseline (P = 0.01) than those whose disease was not reclassified.
Associations between Caveolin-1 Levels and Reclassification
As seen in the distribution of log-transformed Cav-1 levels by reclassification status at 12, 24 and 36 months (Fig. 1) , Cav-1 levels tended to be higher in patients with DR than in those without. The mean log-transformed Cav-1 levels and their 95% CIs by reclassification status and distribution across time indicate that between patients with DR and those without there were statistically significant differences at 6, 12, 18, 24 and 36 months (Fig. 2) . Table 2 shows the results of univariate and multivariate logistic regression analyses. As determined by the Youden index, the optimum cut-off threshold for Cav-1 was 0.624 ng/ mL. In univariate analysis, the risk of DR was significantly associated with having a higher baseline Cav-1 level (OR 1.82, 95% CI 1.24-2.65; P = 0.002), being older (OR 1.45, 95% CI 1.00-2.10; P = 0.05), belonging to a subgroup of patients on AS who chose AS (OR 2.31, 95% CI 1.52-3.51; P = 0.001), having a longer total tumour length at baseline (OR 1.67, 95% CI 1.13-2.49; P = 0.01) or having more than one positive biopsy core (OR 2.31, 95% CI 1.56-3.42; P < 0.001). In the multivariate regression, baseline Cav-1 level (P = 0.001), subgroup assignment (P = 0.001) and number of positive biopsy cores (P = 0.02) were significantly associated with DR. Patients who had a higher level of baseline Cav-1 belonged in a subgroup of patients who chose AS (group II), had more than one positive biopsy core, and had a higher risk of DR. We also performed a subgroup analysis for the 473 patients with 3+3 GS, and observed similar multivariate analysis results (data not shown).
Based on the fitted multiple logistic regression model and the estimated OR for each covariate, a score of 0, 1 or 2 was assigned to each level of a prognostic factor, resulting in a total score for each patient, ranging from 0 to 8 ( Table 3) . The Hosmer-Lemeshow test suggested a goodness of fit of the model (P = 0.13). The area under the receiver-operating characteristic curve (AUC) of 0.66 confirmed that adding Cav-1 to clinical features was superior to relying on clinical features alone and indicated a good performance by the scoring system (Fig. S1) . Table 3 also includes the sensitivity and specificity associated with each total score when dichotomizing patients into low-vs high-risk groups, using total score as a cut-off value. The odds of DR for patients with a total score of ≥4 were 125% higher than the odds for those with a total score <4 (OR 2.25, 95% CI 1.46-3.46; P < 0.001). We also assessed the internal validity of the scoring system using 1000 bootstrap samples, and 96.4% of the time the scoring system was shown to be significantly 
Other Associations
There was no significant association between log-transformed Cav-1 levels and GS and testosterone levels or logtransformed Cav-1 levels and statin use; however, GS was significantly associated with baseline Cav-1, and statin use was significantly associated with testosterone level. The multiple logistic regression analysis indicated that there was a significant association between the log-transformed baseline Cav-1 level and reclassification related to upgrading of GS (OR 1.4; P = 0.01) or reclassified related to other reasons (OR 1.32; P = 0.05 [data not shown]).
Discussion
In the present study in 542 patients enrolled in AS, baseline plasma Cav-1 levels were significantly associated with DR (OR 1.82; P = 0.002). Furthermore, a multivariate prognostication model, adjusted for age, baseline total tumour length, risk group and number of positive biopsy cores, indicated that a high baseline Cav-1 level was significantly associated with the risk of DR (OR 1.91, 95% CI 1.28-2.84; P = 0.001). CAPRA was not predictive of early DR, and, in fact, after adjusting for CAPRA in a multivariate regression analysis, we found Cav-1 was still predictive of DR, further supporting the utility of Cav-1 as a prognostic biomarker. As a secondary analysis, we also fitted a multivariable Cox regression model for the time to DR. The results are similar in that Cav-1 remained a significant predictor for the risk of DR (P = 0.003) after adjusting for the effects of age, risk group, baseline total tumour length and number of positive biopsy cores. Validation of these results could lead to adding new biological criteria that will refine AS patient selection by improving performance of the biopsy, individualizing monitoring strategy, and improving timing of active intervention.
Currently, any triggers for early intervention in AS are mainly pulled by changes in disease on surveillance biopsies, including histological grade, number of tumour-containing cores and tumour length. This explains why a close relationship links increases in tumour volume to dedifferentiation [23, 24] . Prostate biopsies are, however, vulnerable to inherent sampling bias, which may threaten identification of true dedifferentiation (progression). Sampling bias vulnerability was a major focus in two AS studies characterized by a short interval between biopsies [25, 26] .
The strengths of the present study include its large sample size, strict criteria for patient inclusion, and use of highsensitivity assays. Moreover, to the best of our knowledge this is the first longitudinal investigation of a potential blood-based biological biomarker in AS. Limitations include the narrow patient sample: most patients were white and had clinical stage cT1c disease with a GS of 6 and there was also a lack of MRI data to analyse. This study focused on only one plasma biomarker, whereas a panel of biologically related biomarkers has long been sought to improve early progression prediction accuracy. We decided to study Cav-1 levels longitudinally in an attempt to discover if biomarker fluctuation occurred close to the time at which progression occurred, but no association was found; however, the results showed consistently elevated Cav-1 levels for those with DR from the beginning of the surveillance period. These results could mean that patients with high Cav-1 levels harboured cryptic, unbiopsied prostate cancer cells of greater clinical potential and possibly higher GS, at the time of initial biopsy.
Aside from Cav-1, other plasma biomarkers have been suggested as predictive of DR. Tosoian et al. [27] associated [-2]proPSA with biopsy-detected DR in patients with prostate cancer undergoing AS, and after studying 167 men for a median of 4.3 years, these investigators found that measures based on [-2]proPSA, such as the Prostate Health Index (PHI), could predict reclassification by biopsy. The 4Kscore was also found to be a significant predictor of reclassification as defined by a Gleason score ≥7 [28] .
Lin et al. [29] analysed scores of PCA3, a prostate-specific non-coding RNA, and TMPRSS2-ERG generated from urine samples from nearly 400 patients undergoing AS and showed that both stratify risk of having aggressive cancer as defined by higher tumour volume or higher GS. When authors evaluated the receiver-operating characteristic curve analysis of these biomarkers for predicting high Gleason grade (≥7), they found that each one of them independently had an AUC near 0.66; nevertheless, the addition of the markers from the AUC analysis was not more significant than PSA prediction alone (P = 0.08).
The threshold for triggering clinical intervention is often left to the treating physician and to patients, and three Although MRI has not been incorporated in any AS guidelines yet, several studies support the hypothesis that MRI can predict an increased risk of DR [5] ; however, in this era of cost containment, unfortunately, a large proportion of insurance companies decline to cover the cost of MRI in the setting of AS in the USA. Schoots et al. [30] reviewed MRI use in men undergoing AS and, despite the small number of patients, it became evident that MRItargeted biopsies led to discovery of DR in 1:3 to 1:2 men. Based on these results, it seems that MRI could become part of the ongoing surveillance of AS cohorts. Although data are insufficient at this point to support replacing standard repeat biopsy with MRI-targeted biopsy [30] , integrating MRI imaging with detection by blood based-biomarkers may be the best way to improve patient selection, stratification and monitoring (e.g. a decrease in the frequency of surveillance biopsies) in AS.
Given the complexities of the molecular basis and the multistep processes involved in disease progression of early prostate cancer, blood-based biomarkers prognostic of true disease progression possess transformative promise. Cav-1 is the first biomarker detectable in blood that has been shown not only to participate in prostate cancer progression but also to be predictive of early disease progression, and the discovery of this duality expands the library of known clinicopathological parameters in patients undergoing AS. Although these findings have had no impact on clinical practice so far, if validated, monitoring plasma Cav-1 levels may improve risk stratification and thereby increase predictive capacity for identifying patients on AS who are at higher risk of early disease progression. This will lead to a personalized monitoring strategy of hypervigilance for patients at higher risk of disease progression and a less intensive schedule for those who could be spared biopsies and/or early active intervention.
In conclusion, Cav-1 has not only been shown to participate in prostate cancer progression but also to predict DR. The discovery of this duality expands the library of known clinicopathological parameters in patients undergoing AS and may increase predictive capacity for identifying AS patients at higher risk of DR. This capability will lead to a personalized monitoring strategy of hypervigilance for patients at higher risk of DR and a less intensive schedule for those who could be spared biopsies and/or early active intervention.
